Merck Sharp and Dohme (UK) Limited will use the information you provided to send you relevant marketing
materials. We will also use this information to validate that you are a healthcare professional. In the
cases where this fails, we'll securely share your registration data with MSD-approved partners to
support any manual validation process. Please see our full HCP Privacy Notice for further details on how we process your personal
information, our contact details, international transfers, and safeguards we put in place to protect
your information.
Activate Account
Congratulations!
You now have an MSD Connect profile!
To access your content, please click the Continue button below
KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1
ascGeneral Itemother|Oncology|Keytruda|HNSCC-monopublicationdatetypeofcontent|therapeuticgroup|localproductname|otherdate01250tcm:4244-1174057KEYTRUDA monotherapy for HNSCC: Adverse events summary leaflet/static/mciuk/images/msdc_keytruda_hnscc_mono_thumbnail.png/training-resources/keytruda/hnscc/mono-summary-aeosi.xhtml<p xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"> </p><a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_hnscc_mono_thumbnail.pngpublishDateTime2020-12-18T09:41:54assetIdtcm:4244-1174057pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2018-11-05codextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeDownloadable PDFassetfranchiseOncologyasset_descriptionasset_purposeEducateasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-693520KEYTRUDA® (pembrolizumab) Mode of Action/static/mciuk/images/keytruda_moa@2x.png/training-resources/keytruda/moa.xhtml<p xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"> </p><a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda_moa@2x.pngpublishDateTime2021-02-01T14:36:14assetIdtcm:4244-693520pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsMOA,Mode of action,Dual ligand blockade,anti-PD1,Non-small cell lung cancer,NSCLC,Keytruda,pembrolizumab,immunotherapyspecialityexpirationdatehotpublicationdate2018-11-06codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionThis page contains video information on the mode of action for KEYTRUDA▼ (pembrolizumab) and is intended only for UK Healthcare Professionals.asset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00
ascGeneral Itemother|Oncology|Keytruda|HNSCC-monopublicationdatetypeofcontent|therapeuticgroup|localproductname|otherdate01250tcm:4244-1174057KEYTRUDA monotherapy for HNSCC: Adverse events summary leaflet/static/mciuk/images/msdc_keytruda_hnscc_mono_thumbnail.png/training-resources/keytruda/hnscc/mono-summary-aeosi.xhtml<p xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"> </p><a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_hnscc_mono_thumbnail.pngpublishDateTime2020-12-18T09:41:54assetIdtcm:4244-1174057pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2018-11-05codextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeDownloadable PDFassetfranchiseOncologyasset_descriptionasset_purposeEducateasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-693520KEYTRUDA® (pembrolizumab) Mode of Action/static/mciuk/images/keytruda_moa@2x.png/training-resources/keytruda/moa.xhtml<p xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"> </p><a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda_moa@2x.pngpublishDateTime2021-02-01T14:36:14assetIdtcm:4244-693520pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsMOA,Mode of action,Dual ligand blockade,anti-PD1,Non-small cell lung cancer,NSCLC,Keytruda,pembrolizumab,immunotherapyspecialityexpirationdatehotpublicationdate2018-11-06codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionThis page contains video information on the mode of action for KEYTRUDA▼ (pembrolizumab) and is intended only for UK Healthcare Professionals.asset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00
Patient management
ascGeneral Itemother|Oncology|Keytruda|HNSCC-patientpublicationdatetypeofcontent|therapeuticgroup|localproductname|otherdate00150tcm:4244-1147312Download the ‘KEYTRUDA® (pembrolizumab) in HNSCC and treatment modifications for associated immune-related adverse events’ guide/static/mciuk/images/msdc_keytruda_hnscc_irae_thumbnail.png/training-resources/keytruda/hnscc/irAE-slide-deck.xhtml<p xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"> </p><a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>unbranded/static/mciuk/images/msdc_keytruda_hnscc_irae_thumbnail.pngpublishDateTime2020-11-26T09:30:50assetIdtcm:4244-1147312pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2019-03-04codextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeasset_content_classificationasset_accessibilityasset_publisherreadtimehashtags00
